Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FJUW3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,980
Award facts
- Contract value 100% obligated
- $13,979.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,979.52 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector units. The delivery order, issued on December 30, 2025, with an ultimate completion date of January 22, 2026, is structured as a firm fixed-price contract with no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This award carries no subcontractor relationships and represents a routine pharmaceutical supply transaction within DMS Pharmaceutical Group's established federal contracting portfolio.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide. The parent IDC, designated contract SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and positions DMS Pharmaceutical Group as a regional prime vendor contractor through December 31, 2036. The company's extensive product portfolio includes branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, supporting the recurring pharmaceutical needs of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FJUW3?
SPE2DR26FJUW3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FJUW3 worth?
The government has obligated $13,980 on SPE2DR26FJUW3.
Is contract SPE2DR26FJUW3 an order under another contract?
Yes. SPE2DR26FJUW3 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUW3 competed?
The extent of competition for SPE2DR26FJUW3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award